You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Safety of intraarticular N-acetylglucosamine

    SBC: ARTYX PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy a ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Radiosensitization by modulating inhibitors of apoptosis

    SBC: Ascenta Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Radioresistance markedly impairs the efficacy of tumor radiotherapy and involves anti-apoptotic signal transduction pathways that prevent radiation-induced cell death. The inhibitors of apoptosis proteins (IAP) are important intrinsic cellular inhibitors of apoptosis, highly expressed in prostate and lung cancer cells, and play an important role in resistance ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Small Animal Handling Devices for Multiplatform Imaging

    SBC: ASI INSTRUMENTS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Small animal imaging initiatives are growing rapidly due to the enormous potential for improved understanding and treatment of human disease through animal imaging. At present, every radiologic modality available for use in humans has been adapted for small animal use. Other modalities have been devised solely for the purpose of in vivo imaging of research anim ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  4. Robotically Assisted Mouse Interventions

    SBC: ASI INSTRUMENTS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Monitoring the effects of pharmaceutical or radiation intervention in cancer patients is an important tool in the management of disease. Current methods for monitoring tumor response to therapy using imaging include CT and PET scanning. Emerging methods include functional and molecular imaging. In addition to the use of imaging to visually assess tumor growth, ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  5. A targeted peptide for PET imaging of cancer

    SBC: ATTENUON, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): ATN-161 (Ac-PHSCN-NH2) is a five amino acid peptide with potent anti-tumor, anti-angiogenic and anti-metastatic activity that specifically localizes to tumor cells and tumor endothelium. ATN-1 61 binds to several fully activated integrins which are involved in angiogenesis, metastasis and tumor growth and are present in both tumor and angiogenic endothelial ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. AEGIS: A Pixel-array Readout IC for Gamma-ray Imaging

    SBC: Augustine Engineering            Topic: N/A

    DESCRIPTION (provided by applicant): CdZnTe arrays are promising detectors for improving nuclear medicine imaging, but existing CdZnTe cameras have limited spatial resolution and small numbers of pixels (space bandwidth product = SpBW). We show that major performance improvements will require high SpBW (>10A5) and small pixels (high resolution). The best approach to obtaining high SpBW detectors i ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Novel lipid-based therapies for cystic fibrosis

    SBC: AVRION MOLECULAR, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Although the genetic cause of cystic fibrosis (CF), a lethal autosomal disorder, has been known for over a decade, an effective therapeutic method is still lacking. Pulmonary disease remains the major cause of morbidity and mortality in CF. The CF lung is marked by dysregulated inflammation and chronic infection, the end result being progressive bronchiectatic ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  8. Mobile Training of Skilled Support Personnel

    SBC: BANDEMAR NETWORKS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant) Skilled Service Personnel (SSP) support emergency response organizations during an emergency incident involving weapons of mass destruction and include laborers, operating engineers, carpenters, ironworkers, sanitation workers and utility workers. SSP called to an emergency incident rarely have recent detailed training on the chemical, biological, radiological, ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. New Opioids for Alcoholism

    SBC: BEHAVIORAL PHARMA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Highly potent, orally active, metabolically stable, long-lived opioid agents for the treatment of alcoholism that have decreased side effects such as nausea, addiction liability, immunosuppression and respiratory depression represents a great unmet need. While a mu opioid receptor antagonist is currently approved by the FDA for alcoholism, it possesses several ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Progenitor assay to screen proteins/molecules for treatment of type1 diabetes

    SBC: BETASTEM THERAPUETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Human embryonic stem cells (HuES) have the potential to generate an unlimited source of beta/islet cells for transplantation, however the biologic factors required for this process have been difficult to ascertain partly due to the lack of stage specific in vitro cell assays. Recently, we have developed a murine in vitro pancreatic stem/progenitor colony assay ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government